Latest Revalesio News & Updates

See the latest news and media coverage for Revalesio. We track all announcements, press releases, and industry mentions in real time, all in one place.

Revalesio

Clinical-stage pharmaceutical company developing neurological treatments

revalesio.com

Headquarters: Tacoma, United States
Company type: Private company
Number of employees: 20–50

Last updated Today

Latest news about Revalesio

In short: Revalesio reported positive clinical data for its candidate RNS60, highlighting its potential in treating both stroke and ALS.

Company announcements

April 16 Revalesio

Revalesio shares RNS60's positive stroke outcomes

A study in Stroke: Vascular Interventional Neurology shows patients receiving high-dose RNS60 with EVT had shorter hospital stays than EVT alone.

March 5 Revalesio

Revalesio presents stroke treatment advances with RNS60 at ASENT meeting

Acting CMO Jordan Dubow showcases Phase 2 RESCUE trial data on infarct reduction and outcomes. VP Andreas Kalmas presents post hoc analysis showing shorter hospital stays and higher home discharges.

19 November 2025 Revalesio

Revalesio presents Phase 2 RESCUE trial analysis at SVIN 2025

The post-hoc analysis highlights RNS60's potential to shorten hospital stays and increase home discharges for stroke patients. Presentation occurs November 21 in Orlando.

4 November 2025 Revalesio

Revalesio prepares for Phase 3 stroke trial

Inspired by stroke community momentum, they aim to improve patient outcomes from research.

Media coverage

March 5 Yahoo Finance

Revalesio to Present Advances in Stroke Treatment with RNS60 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced its participation in the American Society for Experimental Neurotherapeutics (ASENT...

14 July 2025 KXAN

Revalesio to Present Phase 3 Trial Design and Post Hoc Analysis of Phase 2 RESCUE Trial of RNS60 in Acute Ischemic Stroke at the SNIS 22nd Annual Meeting

TACOMA, Wash., July 14, 2025 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that two abstracts...

9 October 2024 KFOR

Revalesio's Investigational RNS60 Extended Survival in Patients with Amyotrophic Lateral Sclerosis (ALS) in Post-Hoc Analysis of Phase 2 Investigator-Sponsored Trial

TACOMA, Wash., Sept. 17, 2024 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced the publication of...

7 February 2024 Morningstar

Revalesio Presents Additional Analyses from the Phase 2 RESCUE Clinical Trial for RNS60 in Acute Ischemic Stroke

About Revalesio Revalesio is a clinical-stage pharmaceutical company with a vision to change the future of treatment for acute and chronic neurological disorders. The company's...

Never miss news about Revalesio

Track Revalesio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Revalesio competitors & trending companies

Browse news for competitors to Revalesio and other trending companies.